CDER Said No to 6 Peptides. Why Did HHS Say Yes?
HHS's 30 Oct 2026 peptide compounding policy explains why it went ahead despite CDER's advice. See the three reasons it gives and what stays interim.
Summary. The draft peptide compounding policy that the Department of Health and Human Services published on 30 October 2026 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496) openly departs from the advice of FDA's own drug center. According to the policy text, each of the six peptide bulk drug substances it covers sat in FDA's interim "Category 2" from September 2023 until 22 April 2026, and HHS notes that neither the placement nor the removal changed their legal status under section 503A. FDA's Center for Drug Evaluation and Research (CDER) recommended against adding them to the 503A bulks list, while FDA's Pharmacy Compounding Advisory Committee voted in favour. HHS, through the Office of the Secretary rather than FDA, chose interim enforcement discretion with conditions instead. Our FDA Peptide Compounding Policy Tracker follows each step.
Research context (RUO). HHS gives a threefold justification. First, it says the characterisation record has changed: lot-specific certificates of analysis from FDA-registered facilities now report identity, impurity, endotoxin, microbial and residual-solvent results that CDER had found missing. Second, it says historical use is now documented and quantified. Third, it describes CDER's safety concerns as largely inferential or mechanistic rather than observed, and points to the policy's conditions as mitigation: lot-level testing, single-ingredient products and serious adverse event reporting to FDA's MedWatch program. Appendix B also attaches substance-specific limits to each of the six. HHS states the policy applies only until a substance is addressed in a final rule and that it may revisit the policy; it is non-binding, is not an FDA approval and adds nothing to the 503A bulks list. Comments on the docket are open on regulations.gov until 13 November 2026. For laboratories, the argument rests heavily on documentation, which is why reading a full lot-level COA matters; our Academy chapter HPLC and mass spectrometry explained covers the two core identity and purity methods. The policy concerns compounding for patients, not research-grade material.
This summary is for research-community awareness only and is not legal advice. For research use only. Not for human or veterinary use.